Live Breaking News & Updates on Loreda Holdings

Stay updated with breaking news from Loreda holdings. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

EBT-101 is a CRISPR-based therapeutic being developed as a potential functional cure for people living with HIVFirst-in-human trial is now open for enrollment SAN FRANCISCO, Jan. 27, 2022 (GLOBE NEWSWIRE) ....

United States , San Francisco , Robert Flamm , Kostenloser Wertpapierhandel , Lisa Danzig , Daniel Dornbusch , John Fraunces , Rachelm Presti , Excision Biotherapeutics Inc , Loreda Holdings , Burns Mcclellan Inc , Temple University , Chief Executive Officer , Chief Medical Officer , Associate Professor , Washington University School , Principal Investigator , Greatpoint Ventures , Norwest Venture Partners , Adjuvant Capital , Cota Capital , Celesta Capital , Indusage Partners , Olive Tree , Anzu Partners , Silverridge Venture Partners ,

Investegate |Excision BioTherapeutics Announcements | Excision BioTherapeutics: Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

Investegate announcements from Excision BioTherapeutics, Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV ....

United States , San Francisco , Robert Flamm , Lisa Danzig , Daniel Dornbusch , John Fraunces , Rachelm Presti , Excision Biotherapeutics Inc , Loreda Holdings , Burns Mcclellan Inc , Temple University , Potential Cure , Chief Executive Officer , Chief Medical Officer , Associate Professor , Washington University School , Principal Investigator , Greatpoint Ventures , Norwest Venture Partners , Adjuvant Capital , Cota Capital , Celesta Capital , Indusage Partners , Olive Tree , Anzu Partners , Silverridge Venture Partners ,

Excision BioTherapeutics Appoints Infectious Disease Expert Sumathi Sivapalasingam, M.D, as Head of Translational Medicine

Excision BioTherapeutics Appoints Infectious Disease Expert Sumathi Sivapalasingam, M.D, as Head of Translational Medicine - read this article along with other careers information, tips and advice on BioSpace ....

United States , San Francisco , Eric Ando , Daniel Dornbusch , Sumathi Sivapalasingam , Ryo Imai Robert Flamm , Centers For Disease , Experimental Sciences At Regeneron Pharmaceuticals , Infectious Disease Division , School Of Medicine , Epidemic Intelligence Service , Burns Mcclellan Inc , Early Clinical Development , Temple University , Diarrheal Diseases Branch , Bomu Medical Center , Loreda Holdings , Excision Biotherapeutics Inc , Swarthmore College , Chief Executive Officer , Senior Director , Experimental Sciences , Regeneron Pharmaceuticals , Emergency Use Authorization , Attending Physician , Clinical Scientist ,

Excision BioTherapeutics Appoints Infectious Disease Expert

SAN FRANCISCO, May 27, 2021 (GLOBE NEWSWIRE) Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral. ....

United States , San Francisco , Eric Ando , Daniel Dornbusch , Sumathi Sivapalasingam , Ryo Imai Robert Flamm , Centers For Disease , Experimental Sciences At Regeneron Pharmaceuticals , Infectious Disease Division , School Of Medicine , Epidemic Intelligence Service , Burns Mcclellan Inc , Early Clinical Development , Temple University , Diarrheal Diseases Branch , Bomu Medical Center , Loreda Holdings , Excision Biotherapeutics Inc , Swarthmore College , Chief Executive Officer , Senior Director , Experimental Sciences , Regeneron Pharmaceuticals , Emergency Use Authorization , Attending Physician , Clinical Scientist ,

Excision BioTherapeutics Completes $60 Million Financing to Advance CRISPR-Based Infectious Disease Programs Financing will support advancement of lead HIV potential cure program into clinical development

Published: Feb 17, 2021
SAN FRANCISCO, Feb. 17, 2021 (GLOBE NEWSWIRE) Excision BioTherapeutics Inc. (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the completion of a $60 million financing. The proceeds will be used to advance Excision’s lead candidate, EBT-101, into a Phase 1/2 clinical trial in patients with chronic HIV infection. The financing will also support preclinical programs including EBT-103 targeting JC Virus for Progressive Multifocal Leukoencephalopathy (PML), EBT-104 for Herpes Simplex Virus, and EBT-107 for Hepatitis B.
The financing round was led by GreatPoint Ventures with support from existing investor ARTIS Ventures. New investors include Adjuvant Capital, Norwest Venture Partners, Anzu Partners, Cota Capital, WRVI Capital, IndusAge Partners, Loreda Holdings, and Olive Tree Capital. Ashok Krishnamurthi, Managing Partner at GreatPoint Ventures, will join the Bo ....

United States , San Francisco , Ashok Krishnamurthi , Eric Ando , Kamel Khalili , Daniel Dornbusch , Laurah Carnell , Vasudev Bailey , Ryo Imai Robert Flamm , Kamel Khalili Is Co , Excision Biotherapeutics Inc , Loreda Holdings , Burns Mcclellan Inc , Neuroaids Center , Temple University , Department Of Neuroscience , Progressive Multifocal Leukoencephalopathy , Herpes Simplex Virus , Greatpoint Ventures , Adjuvant Capital , Norwest Venture Partners , Anzu Partners , Cota Capital , Indusage Partners , Olive Tree , Managing Partner ,